TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07349693: Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma

Sponsor: Everfront Biotech Co., Ltd. · Phase: PHASE2/PHASE3 · Area: ONCOLOGY · Target Enrollment: 175 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$18,036,480

Rescue Site Savings

+$11,892,804

Unlock Full NCT07349693 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07349693 Rescue Dossier →